White Paper Download
As budgets and resources tighten, biopharmaceutical firms and CROs are under pressure to conduct cost-effective, risk-based monitoring of clinical trials. But for many, progress in this area has been slow. But why? And what's helping or hindering the adoption process? In August 2013, Applied Clinical Trials and SAS decided to find out. Working with Strategic Research to conduct in-depth telephone interviews with biopharmaceutical companies and contract research organizations, we gathered insights from directors and senior executives in clinical data management, biostatistics and clinical trial operations. This paper summarizes our findings, including barriers to implementing risk-based monitoring, suggestions for moving forward, and what the ideal system would look like.
Have a SAS profile? To complete this form automatically: log in